- Home
- MLSS vs AKTX Comparison
MLSS vs AKTX Comparison
Compare MLSS & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLSS
- AKTX
- Stock Information
- Founded
- MLSS 1989
- AKTX N/A
- Country
- MLSS United States
- AKTX United States
- Employees
- MLSS N/A
- AKTX N/A
- Industry
- MLSS Industrial Specialties
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- MLSS Health Care
- AKTX Health Care
- Exchange
- MLSS Nasdaq
- AKTX Nasdaq
- Market Cap
- MLSS 42.4M
- AKTX 35.7M
- IPO Year
- MLSS 1995
- AKTX N/A
- Fundamental
- Price
- MLSS $0.64
- AKTX $0.99
- Analyst Decision
- MLSS Buy
- AKTX Strong Buy
- Analyst Count
- MLSS 1
- AKTX 1
- Target Price
- MLSS $1.25
- AKTX $5.00
- AVG Volume (30 Days)
- MLSS 942.3K
- AKTX 33.3K
- Earning Date
- MLSS 08-22-2025
- AKTX 08-22-2025
- Dividend Yield
- MLSS N/A
- AKTX N/A
- EPS Growth
- MLSS N/A
- AKTX N/A
- EPS
- MLSS N/A
- AKTX N/A
- Revenue
- MLSS $8,613,503.00
- AKTX N/A
- Revenue This Year
- MLSS $25.28
- AKTX N/A
- Revenue Next Year
- MLSS $20.75
- AKTX N/A
- P/E Ratio
- MLSS N/A
- AKTX N/A
- Revenue Growth
- MLSS N/A
- AKTX N/A
- 52 Week Low
- MLSS $0.38
- AKTX $0.85
- 52 Week High
- MLSS $1.39
- AKTX $4.22
- Technical
- Relative Strength Index (RSI)
- MLSS 53.53
- AKTX 35.33
- Support Level
- MLSS $0.50
- AKTX $0.96
- Resistance Level
- MLSS $0.68
- AKTX $1.06
- Average True Range (ATR)
- MLSS 0.07
- AKTX 0.05
- MACD
- MLSS 0.02
- AKTX -0.01
- Stochastic Oscillator
- MLSS 86.50
- AKTX 14.89
About MLSS Milestone Scientific Inc.
Milestone Scientific Inc is a biomedical technology company. The company is engaged in pioneering proprietary, technological systems and solutions for the medical and dental markets. The company develops, manufactures, markets, and sells the computer-controlled system for the improved and painless delivery of local anesthetics. The system is marketed in dentistry under the trademark CompuDent and in medicine under the trademark CompuMed. The Company conducts its business through two reportable segments: Dental and Medical.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.